中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03681 中国抗体-B

休市中 07-03 16:08:13

1.300

+0.220

+20.37%

最高1.340	最低1.080	成交量946.20万
今开1.080	昨收1.080	日振幅24.07%
总市值18.03亿	流通市值18.03亿	总股本13.87亿
成交额1,159万	换手率0.68%	流通股本13.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03681","market":"HK","secType":"STK","nameCN":"中国抗体-B","latestPrice":1.3,"timestamp":1783066093414,"preClose":1.08,"halted":0,"volume":9462000,"delay":0,"changeRate":0.20370370370370366,"floatShares":1387000000,"shares":1387000000,"eps":-0.09890617171994508,"marketStatus":"休市中","change":0.22,"latestTime":"07-03 16:08:13","open":1.08,"high":1.34,"low":1.08,"amount":11593182,"amplitude":0.240741,"askPrice":1.3,"askSize":37800,"bidPrice":1.29,"bidSize":48000,"shortable":0,"etf":0,"ttmEps":-0.0971164542067072,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":7,"adr":0,"listingDate":1573488000000,"exchange":"SEHK","adjPreClose":1.08,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":2.1058476196208296,"lotSize":300,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03681/tweets","defaultTab":"tweets","newsList":[{"id":"2648881665","title":"中国抗体-B(03681)：梁芳获委任为公司执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2648881665","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648881665?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:23","pubTimestamp":1783077787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，梁芳女士已获委任为公司执行董事，自2026年7月3日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126071164","title":"港股直击 | 部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126071164","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126071164?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:06","pubTimestamp":1782439605,"startTime":"0","endTime":"0","summary":"部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%，康龙化成升3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184186957","title":"港股直击 | 部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184186957","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184186957?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:03","pubTimestamp":1782439382,"startTime":"0","endTime":"0","summary":"部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%，康龙化成升3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","02162","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642501299","title":"中国抗体-B(03681)：薛蕾已获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2642501299","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642501299?lang=zh_cn&edition=full","pubTime":"2026-06-12 22:34","pubTimestamp":1781274885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，于2026年股东周年大会上批准后，薛蕾女士(薛女士)已获委任为非执行董事，自2026年股东周年大会结束时生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642000854","title":"异动股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642000854","media":"财华网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642000854?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:25","pubTimestamp":1781166306,"startTime":"0","endTime":"0","summary":"06月11日收盘，截至发稿，港股涨幅榜前十名分别为北京体育文化涨幅+43.280%、首钢朗泽涨幅+31.490%、台州水务涨幅+30.770%、康特隆涨幅+29.340%、中国抗体-B涨幅+26.850%、中国智能科技涨幅+23.530%、翼菲科技涨幅+23.000%、怡俊集团控股涨幅+21.410%、天臣控股涨幅+21.030%、康利国际控股涨幅+20.730%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/11162557428059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02442","02553","BK1116","BK1541","BK1183","BK1167","BK1148","00464","06890","BK1241","03681","06871","BK1161","01912","01803","BK1194","BK1214","01201","BK1614","BK1225","01542","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642540222","title":"港股异动 | 中国抗体-B(03681)尾盘涨超25% 公司研发管线丰富 机构看好其重磅BD潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2642540222","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642540222?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:58","pubTimestamp":1781164708,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国抗体-B尾盘涨超25%，截至发稿，涨25.93%，报1.36港元，成交额1809.92万港元。消息面上，今年5月，中国抗体自主研发的全球首创人源化抗gc抗体–新型抗CGC抗体 hC2，在用于治疗斑秃及白癜风的人源化动物模型中的临床前研究结果在美国芝加哥举行的2026年皮肤病学研究学会年会上公布。公司称目前正在针对该抗体进行CMC优化及毒理学研究，并计划最早在2026年第四季度提交治疗斑秃的IND申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1161","03681","BK1574","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132847666","title":"中国抗体-B2026年5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1132847666","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132847666?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:46","pubTimestamp":1780566393,"startTime":"0","endTime":"0","summary":"中国抗体-B于2026年6月4日发布截至2026年5月31日的证券变动月报表。公告显示，公司已发行股份维持在1,386,638,336股，未有新增发行或回购，库存股份数目仍为0股。本月内无新股发行或库藏股转让，期末可能因期权行权而新增发行的股份数目为16,926,100股，若所有已授出期权均行使，合计可发行或转让至库藏的股份数为40,952,409股。公司表示，已遵循香港联交所《上市规则》及相关法律规定开展所有证券发行或库藏股相关事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635593711","title":"中国抗体-B(03681)于2026年SID年会上公布抗CGC抗体(hC2)临床前研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2635593711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635593711?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:16","pubTimestamp":1778757360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 发布公告，本公司自主研发的全球首创人源化抗gc抗体–新型抗CGC抗体 hC2，在用于治疗斑秃及白癜风的人源化动物模型中的临床前研究结果已于2026年5月14日在美国芝加哥举行的2026年皮肤病学研究学会年会上公布。在斑秃模型中，hC2给药显著减少脱发;在白癜风模型中，显著减轻皮肤脱色。我们目前正在针对该抗体进行CMC优化及毒理学研究，并计划最早在2026年第四季度提交我们治疗斑秃的IND申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4006","BK1574","CGC","BK4557","BK4007","SID","03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189763972","title":"中国抗体-B更新4月股份变动月报表 股本规模保持平稳","url":"https://stock-news.laohu8.com/highlight/detail?id=1189763972","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189763972?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:54","pubTimestamp":1778057642,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年5月6日披露截至2026年4月30日止月份的证券变动月报表。报告期内，公司已发行股份数量为1,386,638,336股，与上月末持平，未发生新增发行、回购或注销行为，库藏股份数量亦为0，整体股本规模保持稳定。公司在公告中强调，其就本月涉及的所有证券发行或库存股份出售、转让事宜，均已完成董事会正式授权并遵守香港联交所《上市规则》及相关法律法规的要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150412028","title":"中国抗体-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1150412028","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150412028?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:26","pubTimestamp":1777282005,"startTime":"0","endTime":"0","summary":"2026年4月28日，中国抗体-B在港交所发布公告，拟于股东周年大会上授予董事一项股份购回授权，最高规模可达公司于决议案获通过当日已发行股本的10%。本次购回有望以香港法律及上市规则允许的资金为来源，董事会认为此举符合公司及股东的最佳利益，可望进一步提升回报并优化资本结构。根据公告，若相关议案在定于2026年6月12日举行的股东周年大会上获审议通过，董事会将在有效期内在香港联交所回购最多约10%的股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国抗体-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154059050","title":"中国抗体-B2025年年报：亏损显著收窄 资产净值大幅提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1154059050","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154059050?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:25","pubTimestamp":1777281955,"startTime":"0","endTime":"0","summary":"中国抗体-B公布截至2025年12月31日止年度业绩。报告期内，研发成本为8162.4万元人民币，较上一年度的9475.3万元有所下降；除税前亏损降至1.05亿元人民币，较2024年的1.85亿元人民币显著收窄。在资产负债方面，截至报告期末，公司非流动资产从5.68亿元人民币降至5.18亿元人民币，流动资产则由1.85亿元人民币大幅增至3.90亿元人民币。综合来看，中国抗体-B在2025年于减少亏损、提升资产净值方面取得进展，并继续深耕免疫治疗产品线。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国抗体-B2025年年报：亏损显著收窄 资产净值大幅提升","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160433888","title":"中国抗体-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1160433888","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160433888?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:06","pubTimestamp":1775639174,"startTime":"0","endTime":"0","summary":"中国抗体制药有限公司于2026年4月8日披露截至2026年3月31日的股份变动月报表。报告显示，普通股本月底结存1,386,638,336股，与上月底持平，当月未见新增发行、购回或注销行为。截至3月底，未有行权记录，当月内因行使期权所得资金总额为港币0。报告同时确认，公司遵守香港联合交易所有限公司《上市规则》及适用法律法规。截至2026年3月31日，公司股本总数保持稳定。公告由执行董事、主席兼首席执行官梁瑞安签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624500126","title":"海南海药拟减持中国抗体不超5%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2624500126","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624500126?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:57","pubTimestamp":1775221020,"startTime":"0","endTime":"0","summary":"4月3日，海南海药（000566）发布公告，公司拟通过集中竞价交易及大宗交易的方式减持中国抗体（03681）股份数量不超过6800万股，不超过公司总股本的5%。截至公告披露日前一交易日，公司持有中国抗体1.59亿股股票资产的市值约为2.8亿港元，此次交易旨在优化公司资产结构，提高资产流动性及使用效率。2025年前三季度，海南海药实现收入6.40亿元，归母净利润-2.42亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695191451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK0070","BK0188","03681","BK0146","BK1574","BK0239","BK1161","000566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624591113","title":"中国抗体-B(03681)：SM17治疗特应性皮炎中国2期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624591113","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624591113?lang=zh_cn&edition=full","pubTime":"2026-04-01 17:49","pubTimestamp":1775036988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 发布公告，于2026年3月31日，SM17治疗特应性皮炎的2期临床试验已在中国成功完成首例患者给药。于2025年4月7日，本公司公布SM17在中国针对中重度特应性皮炎患者进行的1b期研究取得积极的顶线结果。该等结果显示SM17作为潜在首个兼具缓解瘙痒及皮肤修复双重疗效的特应性皮炎生物制剂的竞争优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","03681"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623003403","title":"中国抗体-B(03681)：陈海刚辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623003403","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623003403?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:03","pubTimestamp":1774951429,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，陈海刚博士(陈博士)已提呈辞任非执行董事，自2026年3月31日起生效，以便投放更多时间于个人事务;及董汛先生(董先生)已提呈辞任非执行董事，自2026年4月1日起生效，乃由于其其他个人工作及业务承担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622243000","title":"中国抗体-B(03681)：SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622243000","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622243000?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:57","pubTimestamp":1774432620,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 发布公告，本公司董事会欣然宣布SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果。临床报告于2024年第一季度获得，其显示出SM17 具有良好的安全性，并未报告任何与药物相关的严重不良反应。本公司2025年4月7日公布了在中国中重度AD患者中评估SM17初步疗效的概念验证性1b期临床试验的积极主要结果。于2026年2月，SM17用于治疗IBD患者的临床研究新药申请已获中国国家药品监督管理局批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国抗体-B(03681)：SM17在中国进行的给药途径转换1期桥接研究取得良好顶线结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","03681","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621061761","title":"中国抗体-B(03681)授出1157.48万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621061761?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:54","pubTimestamp":1774353294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，于2026年3月24日，公司已根据2022年购股权计划向2名合资格人士授出1157.48万份购股权。购股权赋予承授人权利认购合共1157.48万股公司新股份，但须待承授人接纳后方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120421645","title":"异动解读 | 中国抗体-B盘中大涨5.99%，年度亏损收窄及核心产品临床进展提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1120421645","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120421645?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:21","pubTimestamp":1774333279,"startTime":"0","endTime":"0","summary":"中国抗体-B今日盘中股价大幅上涨5.99%，引起了市场投资者的密切关注。消息面上，公司此前发布了截至2025年12月31日止年度的业绩公告。公告显示，公司年内亏损由2024年度的1.85亿元大幅减少8010万元至约1.05亿元，亏损收窄主要由于公司专注于SM17的1b期临床、转型桥接研究及筹备2期临床试验，其成本低于此前的大规模临床研究。此外，公司的财务状况显著改善，截至2025年底，可动用的资金总额为3.52亿元，较2024年同期的1.41亿元大幅增加。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770297","title":"中国抗体-B(03681)2025年亏损大幅收窄 管线开发及商业化取得重大进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770297","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621770297?lang=zh_cn&edition=full","pubTime":"2026-03-23 22:44","pubTimestamp":1774277065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B 公布2025年业绩，其他收入及收益约2927.1万元，同比增长2.84倍;研究与开发成本为8162.4万元，同比减少13.86%;净亏损约1.05亿元，同比收窄43.29%。旗舰产品舒西利单抗，全球同类首创抗CD–22单抗—于2025年 7月在系统性红斑狼疮治疗的体外研究中取得突破性临床前结果，在小鼠模型中显示出减轻蛋白尿及潜在缓解狼疮性肾炎的前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135630","title":"中国抗体-B(03681)附属终止租赁协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618135630?lang=zh_cn&edition=full","pubTime":"2026-03-12 18:44","pubTimestamp":1773312249,"startTime":"0","endTime":"0","summary":"经考虑本公司优化资源配置及提升营运灵活性的策略，订约方已就提前终止租赁协议展开商讨。经长时间磋商后，订约方均同意终止租赁协议。董事会认为，终止协议对本公司向轻资产制造模式过渡而言属于合理且务实。董事会认为，终止协议不会对本集团的财务状况或营运构成任何重大不利影响，并符合本公司及其股东的整体利益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","03681"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinomab.com","stockEarnings":[{"period":"1week","weight":0.3},{"period":"1month","weight":0.0656},{"period":"3month","weight":-0.2614},{"period":"6month","weight":-0.0647},{"period":"1year","weight":-0.381},{"period":"ytd","weight":-0.0299}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国抗体制药有限公司是一家主要研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司。该公司主要研制以单克隆抗体为基础的生物制剂和新化学实体, 主要产品包括治疗类风湿关节炎的潜在单抗药物SM03。 该公司研发药物还包括有治疗特应性皮炎，哮喘，特发性肺纤维化及其他免疫性疾病潜力的SM17以及针对系统性红斑狼疮, 天疱疮，多发性硬化症及视神经脊髓炎普系疾病的SN1011 。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.001496},{"month":2,"riseRate":0.428571,"avgChangeRate":0.047286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.044577},{"month":4,"riseRate":0.714286,"avgChangeRate":0.048474},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.024206},{"month":6,"riseRate":0.285714,"avgChangeRate":0.017188},{"month":7,"riseRate":0.428571,"avgChangeRate":0.065355},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.139986},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048263},{"month":10,"riseRate":0,"avgChangeRate":-0.071195},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.003752},{"month":12,"riseRate":0.428571,"avgChangeRate":0.081979}],"exchange":"SEHK","name":"中国抗体-B","nameEN":"SINOMAB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国抗体-B,03681,中国抗体-B股票,中国抗体-B股票老虎,中国抗体-B股票老虎国际,中国抗体-B行情,中国抗体-B股票行情,中国抗体-B股价,中国抗体-B股市,中国抗体-B股票价格,中国抗体-B股票交易,中国抗体-B股票购买,中国抗体-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国抗体-B(03681)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国抗体-B(03681)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}